Result:Steady· Market: Flat#One-off gain#Base effect
| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 0.93 |
| Total Income | 5.07 |
| Expenditure | 2.21 |
| PBT | 2.86 |
| Net Profit | 2.05 |
| OPM | — |
| NPM | 40.47% |
| EPS | 1.68 |
Core pharma revenue is negligible in both periods (~₹0.9 Cr) and the 202% PAT growth is driven almost entirely by other income (₹4.14 Cr) off a tiny prior-year base, not operating business growth.
Informational and educational content only. Not investment advice.